Search results
Showing 4651 to 4665 of 7691 results
Recommendation ID TA261/1 Question Further research on the clinical effectiveness of rivaroxaban compared with low molecular weight heparin
Recommendation ID IPG595/1 Question Further research on the safety and efficacy of total distal radioulnar joint replacement for symptomatic
Recommendation ID IPG576/1 Question Further research into extraurethral (noncircumferential) retropubic adjustable compression devices
Recommendation ID IPG383/1 Question Further research into hand allotransplantation should include data on long-term functional outcomes
Recommendation ID IPG512/1 Question Further research into implantation of a shock or load absorber for mild to moderate symptomatic medial
Recommendation ID IPG538/1 Question Further research into joint distraction for ankle osteoarthritis should include comparative studies
Recommendation ID IPG529/1 Question Further research into joint distraction for knee osteoarthritis without alignment correction should
Recommendation ID IPG511/1 Question Further research into open reduction of slipped capital femoral epiphysis should clearly describe details
Recommendation ID IPG380/1 Question Further research into percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision
Recommendation ID TA319/2 Question Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab
Recommendation ID DG22/1 Question Further research into the analytical and clinical validity of the enzyme-linked immunosorbent assay (ELISA)
Recommendation ID TA236/2 Question Further research into whether ticagrelor is particularly beneficial in any clinical or biological subgroups
Recommendation ID IPG405/1 Question Further research into the comparative efficacy and safety of different surgical and ablative treatments
Recommendation ID MTG38/1 Question Further research is needed on the benefits and consequences of detecting preclinical diabetic peripheral
Recommendation ID HST8/1 Question In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and agreed